Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ARVN vs SLDB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SLDB Captures Overall Composite Edge (36.5 SELL vs 52.9 HOLD), While ARVN Leads 4–1 on Growth & Valuation Pillars
SLDB Overall Winner
6-Pillar Tally: ARVN 4 – 1 SLDB (1 Tie)
Matrix Metrics: ARVN 6 – 4 SLDB
As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus SLDB at $6.57 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY).
- Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile SLDB is in a Breakdown options structure phase (RSI 47.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ARVN vs SLDB
ARVN
Arvinas, Inc
$6.74
-1.17% 1D
Market Cap
$449.9M
TTM Revenue
$275M
Forward P/E
17.9x
Beta / 30D Vol
1.40β · 66% Vol
Unified Composite Score
52.9
HOLD
Tech 54.0
Fund 59.0
Flow 71.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
SLDB
Head-to-Head Winner
Solid Biosciences Inc. Common Stock
$6.57
-4.02% 1D
Market Cap
$781.3M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
2.14β · 76% Vol
Unified Composite Score
36.5
SELL
Tech 15.0
Fund 36.0
Flow 70.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (ARVN 4 – 1 SLDB)
1. Valuation Multiples
ARVN
Forward P/E
17.9x
N/M
Trailing P/E
17.9x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
1.3x
N/M
2. Growth & Scale
ARVN
Revenue Growth (YoY)
-98.8%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$275M
N/A
Market Cap
$449.9M
$781.3M
3. Profitability & Quality
SLDB
Gross Margin
96.7%
N/A
Operating Margin
-10.1%
0.0%
Net Profit Margin
-3.5%
0.0%
Return on Equity (ROE)
-1.8%
-76.9%
4. Balance Sheet & Cash Flow
ARVN
Cash Generation (TTM)
-$160M
-$200M
Cash Flow Margin
-58.0%
N/A
Net Cash / Leverage
$81M Net Cash
$106M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ARVN
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
108.7% (25th %ile)
103.7% (15th %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
0.08x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ARVN (6) vs SLDB (4)| Institutional Metric | ARVN | SLDB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $449.9M | $781.3M | SLDB | |
| Trailing P/E Ratio | 17.9x | N/M | ARVN | |
| Forward P/E Ratio | 17.9x | N/M | ARVN | |
| Revenue Growth (YoY) | -98.8% | -100.0% | ARVN | |
| Operating Margin (TTM) | -10.1% | 0.0% | SLDB | |
| Net Profit Margin | -3.5% | 0.0% | SLDB | |
| Return on Equity (ROE) | -1.8% | -76.9% | ARVN | |
| 52-Week Range Position | 5% ($6–$15) | 33% ($4–$11) | SLDB | |
| Beta / 30D Volatility | 1.40β · 66% Vol | 2.14β · 76% Vol | ARVN | |
| Unified Institutional Score | 52.9 / 100 (HOLD) | 36.5 / 100 (SELL) | ARVN | |
| Trailing 12M Revenue (USD) | $275M | N/A | Scale | |
| Gross Profit Margin (TTM) | 96.7% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.3x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$160M ($81M Net Cash) | -$200M ($106M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SLDB +22.02 pp
3M Horizon
ARVN +0.49 pp
6M Horizon
SLDB +24.07 pp
1Y Horizon
SLDB +86.07 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARVN Revenue | SLDB Revenue | ARVN Op. Margin | SLDB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -306.3% | N/A | ARVN |
| FY2019 | $20M | N/A | -281.4% | N/A | ARVN |
| FY2020 | $20M | N/A | -554.1% | N/A | ARVN |
| FY2021 | $50M | $10M | -403.4% | -530.5% | ARVN |
| FY2022 | $130M | $10M | -200.3% | -1315.2% | ARVN |
| FY2023 | $80M | N/A | -511.5% | N/A | ARVN |
| FY2024 | $260M | N/A | -95.0% | N/A | ARVN |
| FY2025 | $260M | N/A | -45.1% | N/A | ARVN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ARVN
BREAKDOWN
Current IV
108.7%
IV Percentile
25th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SLDB
BREAKDOWN
Current IV
103.7%
IV Percentile
15th %ile
Put/Call OI Skew
0.08x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact SLDB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ARVN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SLDB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ARVN vs SLDB Key Questions & Quantitative Answers
As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus SLDB at $6.57 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY). Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile SLDB is in a Breakdown options structure phase (RSI 47.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ARVN leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with SLDB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARVN cumulative revenue shifted +2500.0% while SLDB shifted +0.0%. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLDB.
ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas SLDB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus SLDB (-76.9% ROE) capital efficiency.
In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, SLDB carries 103.7% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.14β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SLDB vs ARVN · Reverse Pair
ARVN vs KYMR
· Sector Peer
ARVN vs DNLI
· Sector Peer
ARVN vs RCUS
· Sector Peer
SLDB vs RGNX
· Sector Peer
SLDB vs MGTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem